These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Nationwide practice patterns in the use of recombinant human bone morphogenetic protein-2 in pediatric spine surgery as a function of patient-, hospital-, and procedure-related factors. Lam SK; Sayama C; Harris DA; Briceño V; Luerssen TG; Jea A J Neurosurg Pediatr; 2014 Nov; 14(5):476-85. PubMed ID: 25171721 [TBL] [Abstract][Full Text] [Related]
4. Off-label innovation: characterization through a case study of rhBMP-2 for spinal fusion. Schnurman Z; Smith ML; Kondziolka D J Neurosurg Spine; 2016 Sep; 25(3):406-14. PubMed ID: 27104282 [TBL] [Abstract][Full Text] [Related]
5. Bone morphogenetic protein use in spine surgery in the United States: how have we responded to the warnings? Guzman JZ; Merrill RK; Kim JS; Overley SC; Dowdell JE; Somani S; Hecht AC; Cho SK; Qureshi SA Spine J; 2017 Sep; 17(9):1247-1254. PubMed ID: 28456674 [TBL] [Abstract][Full Text] [Related]
6. The efficacy of routine use of recombinant human bone morphogenetic protein-2 in occipitocervical and atlantoaxial fusions of the pediatric spine: a minimum of 12 months' follow-up with computed tomography. Sayama C; Hadley C; Monaco GN; Sen A; Brayton A; Briceño V; Tran BH; Ryan SL; Luerssen TG; Fulkerson D; Jea A J Neurosurg Pediatr; 2015 Jul; 16(1):14-20. PubMed ID: 25860982 [TBL] [Abstract][Full Text] [Related]
8. RhBMP-2 is superior to iliac crest bone graft for long fusions to the sacrum in adult spinal deformity: 4- to 14-year follow-up. Kim HJ; Buchowski JM; Zebala LP; Dickson DD; Koester L; Bridwell KH Spine (Phila Pa 1976); 2013 Jun; 38(14):1209-15. PubMed ID: 23392417 [TBL] [Abstract][Full Text] [Related]
9. Routine use of recombinant human bone morphogenetic protein-2 in posterior fusions of the pediatric spine and incidence of cancer. Sayama C; Willsey M; Chintagumpala M; Brayton A; Briceño V; Ryan SL; Luerssen TG; Hwang SW; Jea A J Neurosurg Pediatr; 2015 Jul; 16(1):4-13. PubMed ID: 25860984 [TBL] [Abstract][Full Text] [Related]
10. Effectiveness and harms of recombinant human bone morphogenetic protein-2 in spine fusion: a systematic review and meta-analysis. Fu R; Selph S; McDonagh M; Peterson K; Tiwari A; Chou R; Helfand M Ann Intern Med; 2013 Jun; 158(12):890-902. PubMed ID: 23778906 [TBL] [Abstract][Full Text] [Related]
11. Feasibility of Percutaneous Posterolateral Spinal Fusion With Recombinant Bone Morphogenetic Protein-2 (rhBMP-2): A Comparison With Standard Methods Using an Animal Model Study. Chan CY; Kwan MK; Saw LB; Paisal H Clin Spine Surg; 2017 Mar; 30(2):E138-E147. PubMed ID: 28207623 [TBL] [Abstract][Full Text] [Related]
12. A Systematic Review of Lumbar Fusion Rates With and Without the Use of rhBMP-2. Galimberti F; Lubelski D; Healy AT; Wang T; Abdullah KG; Nowacki AS; Benzel EC; Mroz TE Spine (Phila Pa 1976); 2015 Jul; 40(14):1132-9. PubMed ID: 25955186 [TBL] [Abstract][Full Text] [Related]
13. Recombinant human bone morphogenetic protein-2 as an adjunct for spine fusion in a pediatric population. Abd-El-Barr MM; Cox JB; Antonucci MU; Bennett J; Murad GJ; Pincus DW Pediatr Neurosurg; 2011; 47(4):266-71. PubMed ID: 22310349 [TBL] [Abstract][Full Text] [Related]
14. Editorial: Food and Drug Administration Safety Communication on rhBMP-2 use. Kestle JR J Neurosurg Pediatr; 2015 Jul; 16(1):1-3. PubMed ID: 25860980 [No Abstract] [Full Text] [Related]
15. Bone Morphogenetic Proteins in Anterior Cervical Fusion: A Systematic Review and Meta-Analysis. Zadegan SA; Abedi A; Jazayeri SB; Nasiri Bonaki H; Jazayeri SB; Vaccaro AR; Rahimi-Movaghar V World Neurosurg; 2017 Aug; 104():752-787. PubMed ID: 28315798 [TBL] [Abstract][Full Text] [Related]
16. Off-label use of bone morphogenetic proteins in pediatric spinal arthrodesis. Dodwell E; Snyder B; Wright J JAMA; 2012 Oct; 308(14):1429-32. PubMed ID: 23047351 [No Abstract] [Full Text] [Related]
17. Full-length spp24, but not its 18.5-kDa proteolytic fragment, inhibits bone-healing in a rodent model of spine fusion. Sintuu C; Simon RJ; Miyazaki M; Morishita Y; Hymanson HJ; Taghavi C; Brochmann EJ; Murray SS; Wang JC J Bone Joint Surg Am; 2011 Jun; 93(11):1022-32. PubMed ID: 21655895 [TBL] [Abstract][Full Text] [Related]
19. Transforaminal lumbar interbody fusion with rhBMP-2 in spinal deformity, spondylolisthesis, and degenerative disease--part 1: Large series diagnosis related outcomes and complications with 2- to 9-year follow-up. Crandall DG; Revella J; Patterson J; Huish E; Chang M; McLemore R Spine (Phila Pa 1976); 2013 Jun; 38(13):1128-36. PubMed ID: 23370679 [TBL] [Abstract][Full Text] [Related]
20. Comparison of TLIF with rhBMP-2 versus no TLIF and higher posterolateral rhBMP-2 dose at L5-S1 for long fusions to the sacrum with sacropelvic fixation in patients with primary adult deformity. Rahman RK; Buchowski JM; Stephens B; Dorward IG; Koester LA; Bridwell KH Spine (Phila Pa 1976); 2013 Dec; 38(26):2264-71. PubMed ID: 24108280 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]